12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Obinutuzumab: Phase III data

Data from Stage 1 of the open-label, international Phase III CLL11 trial in about 800 previously untreated CLL patients showed that obinutuzumab plus chlorambucil chemotherapy met the primary endpoint of improving PFS vs. chlorambucil alone. Stage 1 of the 3-arm trial is evaluating obinutuzumab plus chlorambucil compared to chlorambucil alone, while Stage 2 is evaluating obinutuzumab plus chlorambucil compared to Rituxan rituximab plus chlorambucil. Stage 1 also included a pre-planned futility analysis to evaluate the...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >